1. Academic Validation
  2. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality

2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality

  • Toxicol Sci. 2021 Aug 30;183(1):154-169. doi: 10.1093/toxsci/kfab075.
David Hutin 1 Alexandra S Long 1 Kim Sugamori 1 Peng Shao 1 Sachin Kumar Singh 2 Marit Rasmussen 3 Ninni Elise Olafsen 3 Solveig Pettersen 3 Giulia Grimaldi 3 Denis M Grant 1 Jason Matthews 1 3
Affiliations

Affiliations

  • 1 Department of Pharmacology and Toxicology, University of Toronto, Toronto, M5S 1A8 Ontario, Canada.
  • 2 Department of Immunology, Oslo University Hospital, 0372 Oslo, Norway.
  • 3 Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, 0372 Oslo, Norway.
Abstract

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly-adenosine diphosphate (ADP)-ribose polymerase (TIPARP/PARP7), an Aryl Hydrocarbon Receptor (AHR) target gene and mono-ADP-ribosyltransferase, acts as part of a negative feedback loop to repress AHR signaling. This process is prevented by a single H532A mutation in TIPARP that destroys its catalytic activity. We hypothesized that the loss of TIPARP catalytic activity would increase sensitivity to TCDD-induced toxicity in vivo. To test this, we created a catalytically deficient mouse line (TiparpH532A) by introducing a single H532A mutation in TIPARP. Treatment of mouse embryonic fibroblasts or hepatocytes isolated from TiparpH532A mice confirmed the increased TCDD-induced expression of the AHR target genes Cyp1a1, Cyp1b1, and Tiparp. TiparpH532A mice given a single injection of 10 µg/kg TCDD, a nonlethal dose in Tiparp+/+ mice, did not survive beyond day 10. All Tiparp+/+ mice survived the 30-day treatment. TCDD-treated TiparpH532A mice displayed increased expression of AHR target genes, increased steatohepatitis and hepatotoxicity. Hepatic RNA-sequencing revealed 7-fold more differentially expressed genes in TiparpH532A mice than in Tiparp+/+ mice (4542 vs 647 genes) 6 days after TCDD treatment. Differentially expressed genes included genes involved in xenobiotic metabolism, lipid homeostasis and inflammation. Taken together, these data further support TIPARP as a critical negative regulator of AHR activity and show that loss of its catalytic activity is sufficient to increase sensitivity to TCDD-induced steatohepatitis and lethality. Since TIPARP inhibition has recently emerged as a potential Anticancer therapy, the impact on AHR signaling, TCDD and polycyclic aromatic hydrocarbon toxicity will need to be carefully considered under conditions of therapeutic TIPARP inhibition.

Keywords

2,3,7,8-tetrachlorodibenzo-p-dioxin; ADP-ribosylation; ADP-ribosyltransferase diphtheria toxin-like 14 (ARTD14); TCDD-inducible poly-ADP-ribose polymerase (TIPARP); aryl hydrocarbon receptor; poly-ADP-ribose polymerase 7 (PARP7); wasting syndrome.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-136174
    99.86%, PARP7 Inhibitor